Cocrystal Pharma (COCP) Total Non-Current Liabilities (2011 - 2026)
Cocrystal Pharma (COCP) posted Total Non-Current Liabilities of $1.1 million for Q1 2026, down 7.69% sequentially from $1.2 million in Q4 2025, and down 24.09% YoY from $1.4 million in Q1 2025.
Cocrystal Pharma (COCP) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Cocrystal Pharma has reported Total Non-Current Liabilities for 13 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 24.09% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 24.09% YoY) and the FY2025 annual result came in at $1.2 million, down 22.19% from the prior year.
- Total Non-Current Liabilities eased to $1.1 million in Q1 2026 per COCP's latest filing, from $1.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.6 million in Q4 2023 and troughed at $27000.0 in Q1 2023.
- A 5-year average of $912307.7 and a median of $1.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 88.46% in 2023, then jumped 5759.26% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $57000.0 in 2022, then soared by 2729.82% to $1.6 million in 2023, then fell by 6.7% to $1.5 million in 2024, then decreased by 22.19% to $1.2 million in 2025, then retreated by 7.69% to $1.1 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.1 million, $1.2 million, and $1.3 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | 989,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 989,000.00 |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | 57,000.00 |
| Sep 30, 2022 | 119,000.00 |
| Jun 30, 2022 | 177,000.00 |
| Mar 31, 2022 | 234,000.00 |
| Dec 31, 2021 | 298,000.00 |
| Sep 30, 2021 | 358,000.00 |
| Jun 30, 2021 | 290,000.00 |
| Mar 31, 2021 | 336,000.00 |
| Dec 31, 2020 | 379,000.00 |
| Sep 30, 2020 | 425,000.00 |